Pharmacotherapy of Borderline Personality Disorder: Alprazolam, Carbamazepine, Trifluoperazine, and Tranylcypromine

Archives of General Psychiatry

Volumn 45, Issue 2, 1988, Pages 111-119

  Cowdry, Rex William ^a   Gardner, David L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; TRANYLCYPROMINE; TRIFLUOPERAZINE;

ADULT; BORDERLINE STATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DYSPHORIA; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; PERSONALITY DISORDER; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY;

ADULT; ALPRAZOLAM; AMBULATORY CARE; BORDERLINE PERSONALITY DISORDER; CARBAMAZEPINE; CLINICAL TRIALS; COMPARATIVE STUDY; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMAN; PERSONALITY DISORDERS; TRANYLCYPROMINE; TRIFLUOPERAZINE;

EID: 0023857607     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1988.01800260015002     Document Type: Article

References (56)

1. Spitzer RL, Endicott J, Gibbon M: Crossing the border into borderline personality and borderline schizophrenia. Arch Gen Psychiatry 1979;36:17-24.
2. Carroll B, Greden J: Neuroendocrine evaluation of depression in borderline patients. Psychiatr Clin North Am 1981;4:89-99.
3. Soloff PH, Anselm G, Nathan R, Swami S: Dexamethasone suppression test in patients with borderline personality disorder. Am J Psychiatry 1982;139:1621-1622.
4. Baxter L, Edell W, Gerner R, Fairbanks L, Gwirtsman H: Dexamethasone suppression test and Axis I diagnosis of inpatients with DSM-III borderline personality disorder. J Clin Psychiatry 1984;45:150-153.
5. Pope H, Jonas JM, Hudson JI, Cohen BM, Gunderson JG: The validity of DSM-III borderline personality disorder. Arch Gen Psychiatry 1983;40:23-30.
6. Beeber AR, Kline MD, Pies RW, Manring JM Jr: Dexamethasone suppression test in hospitalized depressed patients with borderline personality disorder. J Nerv Ment Dis 1984;172:301-303.
7. Steiner M, Martin S, Wallace JE, Goldman S: Distinguishing subtypes within the borderline domain: A combined psychoneuroendocrine approach. Biol Psychiatry 1984;19:907-911.
8. Torgerson S: Genetic and nosological aspects of schizotypal and borderline personality disorders. Arch Gen Psychiatry 1984;41:546-554.
9. Grunhaus L, King D, Greden JF, Flegel P: Depression and panic in patients with borderline personality disorder. Biol Psychiatry 1985;20:668-692.
10. Akiskal H: Sub-affective disorders, dysthymic, cyclothymic and bipolar II disorders in the borderline realm. Psychiatr Clin North Am 1981;4:25-46.
11. Akiskal HS, Chen SE, Davis GC, Puzantian VR, Kashgarian M, Bolinger JM: Borderline: An adjective in search of a noun. J Clin Psychiatry 1985;46:41-48.
12. Stone M: Contemporary shift of the borderline concept from a subschizophrenic disorder to a subaffective disorder. Psychiatr Clin North Am 1979;2:577-594.
13. Loranger AW, Oldham JM, Tulis EH: Familial transmission of borderline personality. Arch Gen Psychiatry 1982;39:795-802.
14. Liebowitz MR, Klein DF: Interrelationship of hysteroid dysphoria and borderline personality disorder. Psychiatr Clin North Am 1981;4:67-87.
15. Liebowitz MR, Klein DF: Hysteroid dysphoria. Psychiatr Clin North Am 1979;2:555-575.
16. Andrulonis PA, Glueck BC, Stroebel CF, Vogel NG, Shapiro AL, Aldridge DM: Organic brain dysfunction and the borderline syndrome. Psychiatr Clin North Am 1981;4:47-66.
17. Cowdry RW, Pickar D, Davies R: Symptoms and EEG findings in the borderline syndrome. Int J Psychiatry Med 1985;15:201-211.
18. Monroe RR: Episodic Behavior Disorders. Cambridge, Mass, Harvard University Press, 1970.
19. American Psychiatric Association Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, DC, American Psychiatric Association, 1980.
20. Gunderson J, Kolb J, Austin V: The diagnostic interview for borderline patients. Am J Psychiatry 1981;138:896-903.
21. Feighner JP, Aden GC, Fabre LF, Richels K, Smith WT: Comparison of alprazolam, imipramine and placebo in the treatment of depression. JAMA 1983;249:3057-3064.
22. Rush AJ, Erman MK, Schlesser MA, Roffwarg HP, Vasavada N, Khatami M, Fairchild C, Giles D: Alprazolam vs amitriptyline in depressions with reduced REM latencies. Arch Gen Psychiatry 1985;42:1154-1159.
23. Kobayashi K, Inverta Y, Mukawa J: Preferential action of Tegretol to limbic seizure. No To Shinkei 1967;19:199-205.
24. Ballenger NC, Post RM: Carbamazepine (Tegretol) in manic-depressive Illness: A new treatment. Am J Psychiatry 1980;137:782-790.
25. Post RM, Ballenger JC, Uhde TW, Bunney WE Jr: Efficacy of carbamazepine in manic-depressive Illness: Implications for underlying mechanisms, in Post RM, Ballenger JC (eds): Neurobiology of Mood Disorders. Baltimore, Williams & Wilkins, 1984, pp 777-816.
26. Klein DF, Gittelman R, Quitkin F, Rifkin A: Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children, ed 2. Baltimore, Williams & Wilkins, 1980, pp 243-250.
27. Silberman EK, Post RM, Nurnberger J, Theodore W, Boulanger JP: Transient sensory, cognitive and affective phenomena in affective Illness: A comparison with complex partial epilepsy. Br J Psychiatry 1985;146:81-89.
28. Gardner DL, Lucas PB, Cowdry RW: Soft sign neurological abnormalities in borderline personality disorder and normal controls. J Nerv Ment Dis 1987;175:177-180.
29. Gardner DL, Cowdry RW: Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985;142:98-100.
30. Gardner DL, Cowdry RW: Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 1986;143:519-522.
31. Gardner DL, Cowdry RW: Development of melancholia during carbamazepine treatment in borderline personality disorder. J Clin Psychopharmacol 1986;6:236-239.
32. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO: Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986;43:680-686.
33. Faltus FJ: The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. Am J Psychiatry 1984;141:802-803.
34. Leone NF: Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982;43:148-150.
35. Serban G, Siegel S: Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984;141:1455-1458.
36. Soloff PH, George A, Nathan S, Schulz PM, Ulrich RF, Perel JM: Progress in pharmacotherapy of borderline disorders. Arch Gen Psychiatry 1986;43:691-697.
37. Dalby MA: Behavioral effects of carbamazepine. Adv Neurol 1975;11:331-343.
38. Okuma T, Inanaga K, Otsuki S: A preliminary double-blind study of the efficacy of carbamazepine in prophylaxis of manic-depressive Illness. Psychopharmacology 1981;73:95-96.
39. Neppe VM: Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry 1983;44:236-331.
40. Luchins DJ: Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacol Bull 1984;20:569-571.
41. Mathis JA: Carbamazepine for uncontrolled rage outbursts. Lancet 1984;2:1164-1165.
42. Gunderson JG, Kolb JE: Discriminating features of borderline patients. Am J Psychiatry 1978;135:792-796.
43. Fink M, Pollack M, Klein DF: Comparative studies of chlorpromazine and imipramine: I. Drug discriminating patterns. Neuropsychopharmacology 1964;3:370-372.
44. Hedberg DL, Houck JH, Glueck BC: Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. Am J Psychiatry 1971;127:1141-1146.
45. Salzman C, Kochansky GE, Shader RI, Porrino LJ, Harmatz JS, Swett CP Jr: Chlordiazapoxide-induced hostility in a small group setting. Arch Gen Psychiatry 1974;31:401-405.
46. Gaind R, Jacoby R: Benzodiazepines causing aggression, in Gaind R, Hudson BL (eds): Current Themes in Psychiatry. London, Macmillan Publishing Co Inc, 1978, vol 1, pp 371-379.
47. Garbutt JC, Loosen PT, Tipermas A, Prange AJ Jr: The TRH test in patients with borderline personality disorder. Psychiatry Res 1983;9:107-113.
48. Sternbach HA, Fleming J, Extein I, Pottash AL, Gold MS: The dexamethasone suppression and thyrotropin-releasing hormone tests in depressed borderline patients. Psychoneuroendocrinology 1983;8:459-462.
49. Akiskal HS, Rosenthal TL, Haykal RF, Lemmi H, Rosenthal RH, Scott-Strauss A: Characterological depressions: Clinical and sleep electroencephalographic findings separating ‘subaffective dysthymias' from 'character-spectrum disorders.’ Arch Gen Psychiatry 1980;37:777-783.
50. Bell J, Lycaki H, Jones D, Kelwala S, Sitaram N: Effect of preexisting borderline personality disorder on clinical and EEG sleep correlates of depression. Psychiatry Res 1983;9:115-123.
51. McNamara E, Reynolds CF III, Soloff PH, Mathias R, Rossi A, Spiker D, Coble PA, Kupfer DJ: EEG sleep evaluation of depression in borderline patients. Am J Psychiatry 1984;141:182-186.
52. Reynolds CF, Soloff PH, Kupfer DJ, Taska LS, Restifo K, Coble PA, McNamara ME: Depression in borderline patients: A prospective EEG sleep study. Psychiatry Res 1985;14:1-15.
53. Seiver LJ, Coursey RD, Alterman IS: Impaired smooth pursuit eye movement: Vulnerability marker for schizotypal personality disorder in a normal volunteer population. Am J Psychiatry 1984;141:1560-1566.
54. Valzelli L: Psychobiology of Aggression and Violence. New York, Raven Press, 1981, pp 87-95.
55. Heath RG, Mickle WA: Evaluation of seven years' experience with depth electrodes in human patients, in Pamey ER, O'Doherty DS (eds): Electrical Studies of the Unanesthetized Brain. New York, Paul B. Hober, 1960.
56. Mark VH, Ervin FR: Violence and the Brain. New York, Harper & Row Publishers Inc, 1970.